Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients
Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.